# Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

> **NCT00840684** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institut Paoli-Calmettes** · enrollment: 135 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** amsacrine
- **DRUG:** busulfan
- **DRUG:** cytarabine
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** laromustine
- **DRUG:** melphalan
- **DRUG:** mitoxantrone hydrochloride
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** autologous hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00840684
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2011-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00840684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00840684, "Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00840684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*